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To investigate the eﬀects of daily supplementation with docosahexaenoic acid (DHA) on coronary heart disease risks in 38
middle-agedmenwithhypertensionand/orhypercholesterolemiainScotland,aﬁve-weekdouble-blindplacebo-controlleddietary
supplementation with either 2g of DHA or active placebo (1g of olive oil) was conducted. Percent composition of DHA in plasma
phospholipids increased signiﬁcantly in DHA group. Systolic and diastolic blood pressure and heart rate decreased signiﬁcantly in
DHA group, but not in placebo group. High-density lipoprotein cholesterol (HDL-C) increased signiﬁcantly, and total cholesterol
(TC)/HDL-C and non-HDL-C/HDL-C ratios decreased signiﬁcantly in both groups. There was no change in TC and non-HDL-
C. We conclude that 2g/day of DHA supplementation reduced coronary heart disease risk factor level improving blood pressure,
heart rate, and lipid proﬁles in hypertensive, hypercholesterolemic Scottish men who do not eat ﬁsh on a regular basis.
1.Introduction
In Scotland, coronary heart disease (CHD) has been one
of the leading causes of death, and standardized mortality
rates (SDRs) from CHD have been among the highest in
Europe for decades although it has been declining since
the late 1970s [1, 2]. Evidence from our epidemiological
studies showed an inverse relation between death from
CHD and ﬁsh consumption and that ﬁsh consumption in
Scotland was at the lowest level among 24-study populations
in the world [3, 4]. Diets high in saturated fats, low in
ﬁbre, antioxidants, and polyunsaturated fatty acids (PUFAs)
were shown to contribute to the higher mortality rates
for CHD in Scotland [5]. There have been various public
health projects undertaken to facilitate dietary modiﬁcations
as primary means of the prevention of CHD among the
Scottish people. However, dietary eﬀorts to improve CHD
risk in Scotland need as well to emphasize the importance
of increasing intake of ﬁsh and ﬁsh products among the
general population. Sections of populations, which consume
large amounts of marine foods, have a low prevalence of
cardiovascular diseases (CVD) [6, 7]. Our epidemiological
study indicated plasma docosahexaenoic acid (DHA) level
as a useful biomarker of the frequency of ﬁsh intake [8].
The intake of ﬁsh oils has been associated with a signiﬁcant
reduction in blood pressure (BP) [9], triglycerides, and very-
low density lipoprotein cholesterol [10]. The eﬀect of ﬁsh oil
on reducing heart rate (HR), a CVD risk factor, has also been2 International Journal of Hypertension
recognized [11]. We further conﬁrmed a signiﬁcant inverse
association of ω-3 PUFAs and PUFAs to saturated fatty acids
(FAs) ratio with CHD mortality in 25 population samples
drawn in 16 countries [12].
We hypothesize that frequent intake of ﬁsh or ﬁsh
products may reduce CHD risk factors among people who
eatlittleornoﬁshinScotland.Therefore,theobjectiveofthis
studywastoﬁndoutifdietarylongchainPUFAsanddocosa-
hexaenoic acid (DHA) was eﬀective in improving BP, HR,
and lipid proﬁle in hypertensive and hypercholesterolemic
Scottish men.
2.MaterialsandMethods
2.1. Subjects. Study volunteers were recruited in Spring
2001 in the island of Lewis and Harris in the Western
Isles, in the north western part of Scotland. A total of
156 male inhabitants aged 45–59 years from the two areas
were randomly selected using a stratiﬁed approach. First
12 general practitioners were randomly selected from all
the general practitioners on the Isles of Lewis and Harris.
Then, using the age-sex registers of the practices within
which the 12GP principals worked, males within the
speciﬁed age range were randomly selected. The sampling
was proportionate to the numbers on each GP list to
prevent geographical bias. Exclusion criteria included severe
hypertension (SBP ≥180mmHgand/orDBP ≥110mmHg),
the presence of diabetes mellitus and any other chronic
illness that could aﬀect BP or blood lipid concentration
or limit the individual’s ability to participate in the study,
and the use of antihypertensive drugs, cholesterol-lowering
drugs, and any medication known to aﬀect BP or lipid
concentrations. Subjects who withdrew during the inter-
vention period or who failed to collect data completely
were excluded from the analysis. The Research Ethics
Committee of the Western Isles Health Board approved the
study design. Each participant signed an informed consent
form.
2.2.StudyDesign. Thestudywasarandomized double-blind
placebo-controlled trial involving 156 male inhabitants aged
45–59 in the Isles of Lewis and Harris. The study was con-
ducted in two separate stages. Stage 1 was a screening survey
for high-risk subjects, involving a structured questionnaire
to obtain information about demographic characteristics,
medical history and medication, and a clinical evaluation of
height and weight, BP, HR, and fasting blood lipid proﬁle.
14mL samples of overnight fasting blood were collected
and used as baseline data. Blood lipid proﬁle was measured
with a compact, instant blood lipid analyzer. Three BP and
HR measurements were taken with an automatic digital BP
monitor (HEM-970, OMRON, Kyoto, Japan) after about
ten minutes of rest. The average of the three readings is
used in this analysis as baseline data. Weight and height
were measured with participants wearing light clothing
and without shoes. Weight was measured to the nearest
kilogram using a balance scale. Height was measured to the
nearest centimetre using a wall-mounted ruler. A follow-
up examination was conducted after ﬁve weeks of dietary
supplementation.
112 men who were hypertensive (systolic BP (SBP)
≥ 130mmHg) and/or hypercholesterolemic (total choles-
terol (TC) ≥ 220mg/dL or 5.7mmol/L) were eligible to
enter stage 2 of 5-week dietary supplementation, which was
originally a 4-armed trial [13, 14]. Of these four arms,
only those two involving DHA-containing diets and active
placebo diets were relevant as subjects of this report; 25
and 31 participants were assigned to the DHA group and
to the active placebo group, respectively, randomly in a
double-blind fashion. In the DHA group, DHA powder
containing calcium encapsulated DHA (2g/day) mixed in
bread rolls were consumed in addition to the usual diet. The
activeplacebogroupreceivedbreadrollscontainingcalcium-
encapsulated olive oil powder (1g/day). Both powders were
supplied from KITII Co. Tokyo, Japan. The bread rolls were
made by a local baker on Lewis and were identical with
respect to shape, colour, and packaging. Their contents are
shown in Table 1. Fresh rolls were supplied on alternate
days with extra quantities provided when necessary to
accommodate weekends. The fact that the DHA powder was
calcium encapsulated made it resistant to further oxidation
and this also reduced the smell of ﬁsh oil in the food.
The subjects were asked to keep the bread rolls in their
refrigerators until the time of consumption. They agreed to
maintain a stable body weight throughout the study and to
refrain from any signiﬁcant change in physical activity.
Prior to commencement of the dietary intervention,
the participants were given detailed written and verbal
information about the intervention and the supplements.
They were provided with food record forms and were
asked to record their intervention consumption daily. Two
members of the research team visited the participants on two
more occasions during the study period, at weeks 2 and 4,
respectively. During each visit, dietary counselling, adverse
events, compliance assessments, and any medication changes
were documented.
At the beginning of the sixth week, the participants were
invited for the ﬁnal assessment. BP, HR, height, and weight
measurements were repeated as at the preliminary screen-
ing, and fasting blood samples were collected. Participants
completed a one-page questionnaire intended to identify any
adverse eﬀects of the supplements and they were asked to
return the food record forms.
2.3. Laboratory Analyses. The serum and plasma samples
were collected into evacuated tubes (Vacutainer, Wako Com-
pany, Kyoto, Japan), centrifuged at 3000 rpm for 10 minutes
at 23◦C ,a n ds t o r e da t−20◦Ca n da t−70◦C, respectively.
All samples were shipped to the Central Laboratory for
WHO-CARDIAC Study in Kyoto, Japan for the standardized
analyses [15]. Stable conditions (−70◦C) were maintained
during transportation to Kyoto. TC and HDL-C were
measured using an Express-Plus Operator Machine, (Ciba
Corning Diagnostics Corp. West Lake Village USA). Non-
HDL-C was calculated from the diﬀerence between TC andInternational Journal of Hypertension 3
Table 1: Contents of bread rolls.
Nutrients Placebo DHA
Energy (kcal) 251.7 249
Protein (g) 9.1 8.7
Fat (g) 8.5 10.6
Carbohydrate (g) 33.3 28.7
Dietary ﬁbre (g) 1.6 1.5
Sodium (mg) 317.5 301
Olive oil (g) 1.0 0.0
Docosahexaenoic acid (g) 0.0 2.0
Placebo: Olive oil-containing bread rolls; DHA: docosahexaenoic acid-
(DHA-)containing bread rolls
HDL-C: (Non-HDL-C = TC – HDL-C) [16]. Serum TC was
also analyzed on site to detect high risk subjects. These data
were used only for this purpose.
The total lipids were extracted from 500μL of plasma
according to the method of Folch et al. [17]. Heptadecanoic
acid(H-4515SigmaChemicalCompany,St.Louis,Missouri)
was added as an internal standard, chloroform-methanol
(2:1v/v) was added as a solvent, and butylated hydrox-
ytoluene (B-1378 Sigma Chemical Company, St. Louis,
Missouri) was added as an antioxidant. Total phospholipids
were separated by solid-phase extraction using silica gel
columns (237-0075 Wakogel C-200 (Silica Gel), Wako
Pure Chemicals), kept overnight in methanol (137-01823
Methanol, Wako Pure Chemicals), and later evaporated
to dryness. Transmethylation was done using TCI-SU-
3 (triﬂuoromethyl phenyl-trimethylammonium hydroxide)
(5% in methanol) (T-0961, Tokyo Kasei Kogyo Co. Ltd,
Tokyo, Japan) and methanol (1:1v/v).FA methyl esters were
measured using a gas-liquid chromatograph (Shimadzu GC-
14B, Shimadzu Co. Kyoto, Japan). Retention times for each
FA were determined using standards obtained from Sigma
Chemicals (Sigma Chemical Co., St. Louis, Missouri). The
results were integrated on a Shimadzu C-R4A integrator,
and the FA concentrations were reported as percentage
composition of FA in plasma phospholipids.
2.4. Statistical Analysis. Statistical analyses were performed
using SPSS 15.0 for Windows (SPSS Japan Inc., Tokyo,
Japan). The analysis was carried out on an “as treated” basis
in order to estimate the eﬀect of DHA itself. Baseline values
for serum lipids and anthropometric measurements were
takenasthemeasurementsobtainedatthescreeningprocess.
Because FA, HDL cholesterol, and the food consumption
over the intervention period were not normally distributed,
Wilcoxon rank sum tests were applied for the between group
comparisons and Wilcoxon signed-rank tests were applied
forthewithingroupcomparisonsasforthoseparameters.As
for the other parameters that were normally distributed, the
betweengroupdiﬀerencesweretestedbyStudent’st-testsand
the within group diﬀerences were tested by paired Student’s
t-tests. Data are expressed as mean ± SD if not otherwise
speciﬁed. P values <. 05 were considered signiﬁcant.
Table 2: Subjects characteristics at baseline.
Placebo
(n = 23)
DHA
(n = 15)
P
values∗
Age (y) 52.3 ± 4.4 52.7 ± 3.2 .7728
Height (em) 175.6 ± 6.7 176.9 ± 6.1 .5308
Weight (Kg) 83.7 ± 11.8 82.7 ± 12.3 .8009
Body mass index
(kg/m2) 27.1 ± 3.1 26.4 ± 3.3 .4869
Values are presented as mean ± SD. DHA: docosahexaenoic acid.
∗P values between the placebo and DHA group.
3. Results and Discussion
3.1. Results. Out of 56 eligible participants, 10 withdrew
during the 5-week intervention and 46 subjects returned
for the follow-up examination. Prior to the analysis, 3
participants were excluded because of missing data, and
5 more who had not consumed at least 80% of the total
amount of bread rolls according to the food records were
excluded for noncompliance with the diet. Therefore, the
data from 38 subjects were used for analysis, and the number
of the participants in the DHA and the active placebo
group was 15 and 23, respectively. There were no signiﬁcant
diﬀerences in the average rate of the consumption of bread
rolls between the DHA group and the active placebo group
(92.6 ± 6.9% versus 94.8 ± 5.2%, resp., P = .306). The
baseline characteristics of the subjects assigned to the DHA
and active placebo olive oil are shown in Table 2. There was
no signiﬁcant diﬀerence in age, height, weight, and body
mass index between the two groups.
The eﬀects of DHA supplementation on plasma ω-3 and
ω-6 PUFAs are shown in Table 3. Owing to a maintenance
failure, some of the plasma samples were not kept at the
correct temperature of −70◦C for a period, so that the num-
ber of blood samples available for the measurement of FAs
was limited to 34 subjects from placebo and DHA groups.
Percentage composition of DHA in plasma phospholipids
increased signiﬁcantly, more than 3-fold in the DHA group
(P<. 001). When PUFAs levels were analysed in terms of
total ω-3 and ω-6 PUFAs percent composition in plasma
phospholipids,asigniﬁcantincreasewasobservedinthetotal
ω-3 PUFAs in the DHA group (P<. 01). Similarly, in the
placebo group receiving olive oil, a signiﬁcant increase in
the total ω-6 PUFAs was observed (P<. 01). There were
signiﬁcant between group diﬀerences in the change in DHA
and total ω-3 PUFAs.
Table 4 shows the body weight, HR, BP and lipid proﬁles
at baseline and after intervention in the placebo and DHA
groups. There was a signiﬁcant reduction in mean SBP
(P<. 001), DBP (P<. 01), and HR (P<. 05) in
DHA supplemented group but not in the placebo group.
The analysis of serum lipid proﬁles showed an increase in
HDL-C and decrease in TC/HDL-C and non-HDL-C/HDL-
C ratios both in the placebo and DHA groups. There was no
signiﬁcant change in the TC and non-HDL-C during the 5
weeks of intervention in either group.4 International Journal of Hypertension
Table 3: ω-3 and ω-6 fatty acids in plasma phospholipids at baseline and at 5 weeks and change from the baseline.
Fatty acid Placebo (n = 20) DHA (n = 14)
Baseline 5 Weeks Change (5-weeks-baseline) Baseline 5 Weeks Change (5-weeks-baseline)
EPA (C20:5) (%) 1.50 ± 1.13 1.53 ± 0.79 0.04 ± 1.09 1.24 ± 1.30 1.65 ± 1.20 0.41 ± 1.13
DHA (C22:6) (%) 1.58 ± 0.64 1.47 ± 0.64 −0.11 ± 0.78 1.04 ± 0.47 3.40 ± 0.90∗∗∗ 2.36 ± 0.79†††
PUFAs ω-3 series (%) 3.08 ± 1.54 3.00 ± 1.14 −0.07 ± 1.41 2.28 ± 1.61 5.05 ± 1.86∗∗ 2.77 ± 1.64†††
PUFAs ω-6 series (%) 16.0 ± 5.8 19.3 ± 5.1∗∗ 3.38 ± 4.45 17.1 ± 7.0 18.3 ± 4.3 1.29 ± 5.64
ω-3/ω-6 Ratio 0.24 ± 0.18 0.17 ± 0.09∗ −0.07 ± 0.14 0.15 ± 0.13 0.30 ± 0.18∗∗ 0.15 ± 0.14†††
EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, PUFAs: polyunsaturated fatty acids.
PUFAs ω-3 series: EPA + DHA; PUFAs ω-6 series: arachidonic acid + linoleic acid.
Placebo: Olive oil-containing bread rolls, DHA: DHA-containing bread rolls. Values are presented as mean ± SD.
∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001 compared with the baseline. †††P<. 001 compared with the placebo group.
Table 4: Body weight, heart rate, blood pressure, and lipid proﬁles in the two groups at baseline and at 5 weeks.
Parameter Placebo (n = 23) DHA (n = 15)
Baseline 5 Weeks Baseline 5 Weeks
Weight (kg) 83.7 ± 11.8 83.3 ± 11.4 82.7 ± 12.3 83.1 ± 12.3
Heart rate (bpm) 70.7 ± 14.4 67.0 ± 10.3 70.4 ± 9.8 64.8 ± 9.2∗
Systolic BP (mmHg) 132.7 ± 15.9 128.7 ± 16.3 141.4 ± 13.5 133.0 ± 12.9∗∗∗
Diastolic BP (mmHg) 80.3 ± 10.5 77.9 ± 9.7 86.7 ± 10.4 81.9 ± 9.3∗∗
TC (mg/dL) 228.9 ± 36.6 226.4 ± 36.6 253.6 ± 45.9 247.7 ± 40.5
HDL-C (mg/dL) 54.8 ± 12.7 59.3 ± 11.1∗∗ 55.5 ± 17.3 64.1 ± 20.4∗∗
Non- HDL-C (mg/dL) 174.1 ± 39.8 167.2 ± 36.6 198.1 ± 48.7 183.6 ± 42.0
TC/HDL-C 4.4 ± 1.2 3.9 ± 0.8∗∗ 4.8 ± 1.3 4.1 ± 0.9∗∗
Non-HDL-C/HDL-C 3.4 ± 1.2 2.9 ± 0.8∗∗ 3.8 ± 1.3 3.1 ± 0.9∗∗
Placebo: Olive oil-containing bread rolls, DHA: DHA-containing bread rolls. Values are presented as mean ± SD. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001
compared with the baselines.
Figure 1showsthechangesinSBP,DBP,andHRbetween
baseline and after the intervention. In the DHA group, there
were signiﬁcant reductions in SBP, DBP, and HR. However,
there were no signiﬁcant diﬀerences between the two groups
in SBP (DHA group; −8.3mmHg versus placebo group;
−4.9mmHg, P = .19), DBP (DHA group; −4.1mmHg
versus placebo group; −2.3mmHg, P = .38), and HR (DHA
group; −5.6bpm versus placebo group; −3.7bpm, P = .62).
3.2. Discussion. This study evaluated the beneﬁcial eﬀects of
supplementation with DHA on BP, HR, and serum lipids
in hypertensive and/or hypercholesterolaemic Scottish men.
DHA signiﬁcantly reduced BP and HR in the interven-
tion group. HDL-C level was signiﬁcantly increased and
TC/HDL-C and non-HDL-C/HDL-C ratios were therefore
signiﬁcantly decreased both in the DHA supplemented as
well as in the placebo groups.
We demonstrated a 5.8% (8.3mmHg) and 3.7%
(4.9mmHg) reduction in SBP and DBP, respectively over
a ﬁve-week study period, thus conﬁrming that dietary
supplementation with 2g of DHA per day lowered BP in
persons with stable, untreated hypertension. In hypertensive
patients, a modest BP lowering eﬀect has been shown
after ﬁsh oil intake in some [18, 19]b u tn o ta l l[ 20]
studies. As previously shown [9], the greatest decrease in
BP occurred in those persons with the lowest baseline
plasma concentrations of DHA. This may indicate that an
initially high acceptor-pool for PUFAs is important for the
replacement of ω-6 PUFAs by ω-3 PUFAs during ﬁsh oil
intake. Incorporation of ω-3 PUFAs in biomembranes may
favor the production of less vasoconstrictive thromboxane
A3 rather than the arachidonic acid-derived thromboxane
A2 [21]. Or ω-3 PUFAs may interfere with the arterial
baroreceptor of vascular resistance [22] and may thereby
contribute to the reduction in BP.
Our ﬁnding that DHA had no eﬀect on TC or non-HDL-
C is consistent with the ﬁndings by several other studies.
Eslick et al. performed a meta-analysis of randomized trials
of hyperlipidemic subjects and concluded that ﬁsh oil is
eﬀective in reducing triglycerides levels and had no eﬀect
on TC, although there were minor eﬀects on HDL and LDL
cholesterol [23]. Holub also reported in a review article that
the beneﬁts recognized for DHA on risk factors for CVD
are independent of blood cholesterol lowering [24], and
fasting plasma (serum) triglycerides are an important and
independent risk factor for CHD [25].
The present results demonstrated a signiﬁcant increase
in HDL-C of 16.7% (8.6mg/dL) in DHA group. This is
consistent with the result reported by Eslick and Holub that
DHA supplementation has a moderate eﬀect of increasing
HDL cholesterol. In this study, a DHA dose of 2g per day
wassuﬃcienttoprovidebeneﬁcialeﬀects(HDL-Celevation)
without clinically important adverse changes on TC andInternational Journal of Hypertension 5
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Figure 1: Eﬀects of the DHA and placebo on systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR). Placebo:
Olive Oil-containing bread rolls, DHA: DHA-containing bread rolls. Values are shown as mean ± S.E. of the changes between baseline and
after intervention. ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001 compared with the baselines. There was no signiﬁcant diﬀerence between the two
groups in either parameter.
non-HDL-C. That the ratios TC/HDL-C and non-HDL-
C/HDL-C, which are predictors of CHD risk, [16] decreased
(therefore improved) signiﬁcantly in both groups, would
appear to be attributableto this. The increase in HDL-C with
DHAsupplementationmaybemediatedthroughareduction
in cholesteryl ester-triglyceride exchange between HDL-C
and very low-density lipoprotein cholesterol particles as a
consequence of triglyceride lowering. Harris has shown that
triglyceride lowering eﬀects of ω-3 PUFAs appear to be due
to a decrease in the production of hepatic triglycerides and
an increase in the clearance of plasma triglycerides [26].
The placebo group also demonstrated a signiﬁcant
increase in HDL-C of 9.9% (4.5mg/dL) and decrease in
the ratios of TC/HDL-C and non-HDL-C/HDL-C by 8.3%
(−0.5) and 10.2% (−0.5), respectively. These changes would
beattributedtotheeﬀectofactiveplacebocontaining1g/day
of olive oil. The results of this study strongly support the
reported beneﬁcial eﬀect of olive oil, in that it appears to
improve lipid proﬁles, that is, it increases serum HDL-C
while decreasing triglycerides and the TC/HDL cholesterol
ratio [27]. This further emphasizes the importance of
routinely monitoring the eﬀects of intervention strategies
using any of these ratios.
It has been reported in the Framingham Study that
elevated HR may be an independent risk factor for car-
diovascular death in persons with hypertension [28]. There
has also been data of non-Western populations. NIPPON-
DATA80 study showed that high resting HR is an inde-
pendent predictor of cardiovascular and all-cause death for
middle-aged men and women in the Japanese general
population [29]. Mozaﬀarian reported in a meta-analysis of
randomized controlled trials that ﬁsh oil reduces HR, partic-
ularly in those with higher baseline HR or longer treatment
duration, and that these ﬁndings provide ﬁrm evidence that
ﬁsh oil consumption directly or indirectly aﬀects cardiac
electrophysiology in humans [11]. Considering these reports
together, our present result that HR was reduced by 7.5%
(−5.6bpm) in DHA group may explain the eﬀect of ﬁsh oil
that reduces the risks of CVD. Previous CARDIAC large-
population-based analysis also indicated that HR reduction
is signiﬁcantly associated with BP reduction, possibly con-
tributing to CVD risk reduction [30]. The mechanism of
HR reduction by ﬁsh oil is less certain but some possibilities
are discussed. ω-3 PUFAs incorporated into cardiomyocyte
phospholipids [31] may alter ion channel function such as
the modulation of the fast voltage-dependant Na+ currents
[32] and the L-type Ca2+ channels [33]. This would aﬀect
sinus node automaticity or responsiveness. Another possible
mechanism is that by reducing systemic vascular resistance
[34], ﬁsh oil would reduce BP [18, 19] and improve
ventricular eﬃciency, and this would induce a reduction of
HR.
Subject compliance with the study protocol was deter-
mined to be high on the basis of record of counts of leftover
bread rolls and the analysis of the FAs composition in plasma
phospholipids. The latter has been shown to be a suitable
biological marker for dietary ω-3 PUFAs (DHA and EPA)
intake [35].6 International Journal of Hypertension
There were some limitations to our study. Firstly, we had
to use, as an active placebo, olive oil which was supposed to
be good for health because of the ethical consideration of the
study design. Therefore, it was diﬃcult to obtain between-
group signiﬁcant diﬀerences. Secondly, this study is lacking
in some data representing lipid proﬁles. Triglycerides were
not assayed because it was susceptible to the diet and it
was diﬃcult to ask the participants to fast for more than
12 hours. LDL-cholesterol was not analyzed because frozen
serum samples should be sent for the standardized analytical
center in accordance with the WHO-CARDIAC multicenter
study protocol [15]. Apolipoproteins which have received
attention in recent years as CHD risk factors [36]w e r en o t
analysed because it was diﬃcult to set up a standardized
method of analysis at the time when WHO-CARDIAC Study
was designed in 1985 [15]. Thirdly, the sample size was small
because this report was focused on a part of the intervention
study designed to be carried out depending on the baseline
data of diﬀerent high risk populations examined by WHO-
CARDIAC Study.
However, some strengths were also present. Olive oil
and ﬁsh oil, two main sources of fat in the Mediterranean
diet, well known for the beneﬁcial inﬂuence on CVD risks,
were both eﬀective for improving lipid proﬁle, and DHA
contained in ﬁsh oil demonstrated a greater eﬀect on BP and
HR than did olive oil within a limited time period.
4. Conclusion
In conclusion, supplementation with ﬁsh-oil-derived DHA
incorporated into bread rolls reduced BP, HR, TC/HDL-C,
and non-HDL-C/HDL-C ratios and increased HDL-C sig-
niﬁcantly, while did not aﬀect TC or non-HDL-C in men
with hypertension and/or hyper-cholesterolemia in the Isle
of Lewis and Harris, where the ﬁsh intake is relatively low.
These results indicate that the supplementation of DHA
in daily bread is eﬀective in reducing the risk factors of
CHD even in those who do not eat ﬁsh frequently. Still
further research is warranted to more clearly deﬁne the
eﬀects of DHA supplementation on lipid metabolism and
cardiovascular risk.
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